| Line Item | 2025-09-26 | Y/Y |
|---|---|---|
| Revenue | $17.26B | +8.9% |
| Cost of Revenue | $11.18B | +7.6% |
| Gross Profit | $6.08B | +11.4% |
| R&D Expense | $699.0M | +12.6% |
| SG&A Expense | $1.87B | +7.7% |
| Operating Income | $3.21B | +14.8% |
| Pre-tax Income | $3.20B | +14.6% |
| Income Tax | $1.36B | +442.8% |
| Net Income | $1.84B |
| Line Item | 2025-09-26 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.25B | -4.9% |
| Accounts Receivable | $3.40B | +11.4% |
| Inventory | $2.70B | +7.2% |
| Current Assets | $7.97B | +4.4% |
| Total Assets | $25.08B | +9.7% |
| Current Liabilities | $5.12B | +7.9% |
| Long-term Debt | $4.84B | +45.3% |
| Line Item | 2025-09-26 | Y/Y |
|---|---|---|
| Operating Cash Flow | $4.14B | +19.0% |
| Capital Expenditures | $936.0M | +37.6% |
| Investing Cash Flow | -$3.57B | -275.6% |
| Financing Cash Flow | -$629.0M | +78.1% |
| Free Cash Flow | $3.20B | +14.5% |
| -42.3% |
| EPS (Basic) | $6.20 | -40.4% |
| EPS (Diluted) | $6.16 | -40.4% |
| Total Liabilities |
| $12.35B |
| +19.1% |
| Stockholders' Equity | $12.59B | +1.9% |